Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A conversation with Dr. Jeffrey Singer, Cato Institute health policy expert

Dr. Jeffrey Singer is a senior fellow at the Cato Institute and works in the Department of Health Policy Studies. He is a nationally recognized thought leader in health policy, particularly the harmful effects of drug prohibition.

He has written extensively about the importance of harm reduction. He recently published a report titled, “Cops Practicing Medicine”, a well-researched analysis of America’s poorly constructed prohibition policies, and its effects on the patient-doctor relationship.

Main articles:

https://www.cato.org/white-paper/cops-practicing-medicine

https://www.cato.org/study/cops-practicing-medicine

Additional article for reference:

https://www.cato.org/sites/cato.org/files/pubs/pdf/pa-858.pdf

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!